Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Testicular Cancer
Do you cap cisplatin dose in obese patients undergoing chemotherapy in germ cell tumors?
Do you cap BSA at 2 or 2.2 for such patients to prevent Cisplatin neuropathy and CKD?
Related Questions
How would you treat a stage IIIB recurrent seminoma with early recurrence following first-line treatment with VIP?
Would you consider a cycle of EP in a patient with good risk stage IIIB seminoma on BEP but with bleomycin omitted for cycle 3?
How would you treat a patient with ESRD on hemodialysis with good risk metastatic seminoma with bulky retroperitoneal adenopathy?
What treatment would you offer a patient with Down syndrome and stage IIA seminoma?
What is the optimal management of malignant mesothelioma of the tunica vaginalis testis (MMTVT) found incidentally after hydrocelectomy?
Would you recommend VIP x 4 cycles over EP x 4 cycles in a patient with good risk Stage IIIB seminoma but an elevated LDH over 5x upper limit of normal with a 20 pack year smoking history?
How would manage a patient with primary mediastinal NSGCT who has radiographic response but rising AFP while receiving VIP?
Do you recommend pharmacological ADT for a patient with hypogonadism with unfavorable or high risk prostate cancer whose testosterone was castrate (<20) without supplementation?
Would you offer neoadjuvant chemotherapy to high grade T1 urothelial carcinoma in a bladder diverticulum?
Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?